Protective Effect of Angong Niuhuang Against Negative Inflammatory Response and Neurologic Dysfunction After Cardiovascular Surgery

Protective Effect of Angong Niuhuang Against Negative Inflammatory Response and Neurologic Dysfunction After Cardiovascular Surgery (PANDA X)

Status

Not yet recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06723366

Enrollment

120

Registered

2024-12-09

Start date

2025-01-01

Completion date

2025-12-31

Last updated

2024-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Injury, Cardio-pulmonary Bypass, Cardiovascular Surgery, Cerebral Protection

Keywords

Inflammatory Response, cardiopulmonary bypass

Brief summary

Neurologic Dysfunction is one of the main factors contributing to poor outcomes in cardiac surgery patients, except for heart failure. Atherosclerosis of the aorta, a history of cerebral infarction, and cervical artery disease are common clinical risk factors for cerebral neurological dysfunction after cardiac surgery. Results of preclinical studies suggested that Angong Niuhuang Pills (ANPs), a traditional Chinese patent medicine, including realgar, cinnabaris, Bovis Calculus, artificial Moschus, and powdered buffalo horn extract, decreased infarct volume and cerebral edema, and presented anti- atherosclerosis and cardio-protective effects in clinical and preclinical studies. The PANDA X trial is designed as a pilot study to explore the safety and efficacy of ANP in patients with moderate-to-severe neurologic dysfunction after cardiovascular surgery.

Interventions

DRUGAngong Niuhuang Pill (ANP)

Angong Niuhuang Pill (ANP) (3 g/pill, 1 pill/day for 5 days)

OTHERControl (Standard treatment)

Blank control

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* (1) an age \> 18 years, * (2) underwent cardiovascular surgery, * (3) diagnosis of acute neurologic dysfunction, including but not limited acute cerebral infarction of the internal carotid artery system, * (4) a National Institutes of Health Stroke Scale (NIHSS) score ranging from 10 to 20, * (5) a time from symptom onset to randomization within 36 h, * (6) provision of informed consent.

Exclusion criteria

* (1) not suitable for taking ANP after the dialectical process by a traditional Chinese medical doctor, * (2) received ANP within 1 month before stroke onset, * (3) liver failure, * (4) declined to participate in this study.

Design outcomes

Primary

Measure	Time frame	Description
changes in the NIHSS score	after 14 days of randomization	a National Institutes of Health Stroke Scale (NIHSS) score ranging from 10 to 20

Countries

China

Contacts

Primary ContactHong Liu, MD

dr.hongliu@foxmail.com18801281613

Backup ContactYong-feng Shao, MD

yfshaojph@sina.com02568303101

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026